Melinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA Pathogens
September 18, 2017 08:00 ET
|
Melinta Therapeutics
NEW HAVEN, Conn., Sept. 18, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held commercial-stage company developing novel antibiotics to treat serious bacterial infections, announced...
Melinta Therapeutics Demonstrates Potential of Pyrrolocytosine Candidate against Gonorrhea
June 05, 2017 12:45 ET
|
Melinta Therapeutics
New Haven, Conn., June 05, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced that an oral...
Melinta Therapeutics Updates Pyrrolocytosine and Enhanced Macrolide Programs at ECCMID Showcasing Company’s Structure-Based Drug Design
April 21, 2017 09:56 ET
|
Melinta Therapeutics
New Haven, Conn, April 21, 2017 (GLOBE NEWSWIRE) -- Melinta Therapeutics, a privately held company developing novel antibiotics to treat serious bacterial infections, announced today that...